디를로타피드

용도

• Weight Loss Phase (First 14 days)
• Weight Loss Phase (Days 15 to 28)
• Weight Loss Phase (Subsequent Months)
• Weight Management Phase

투여 방법

가능한 부작용

• Vomiting (especially during the first month or 3-4 hours post-dose)
• Diarrhea
• Lethargy
• Anorexia
• Salivation
• Constipation
• Dehydration
• Elevated serum hepatic transaminases

주의사항 및 금기

• Cats (high risk of hepatic lipidosis)
• Dogs with liver disease
• Dogs receiving long-term corticosteroid therapy
• Unmanaged endocrine disease (e.g., hyperadrenocorticism/Cushing's disease)
• **Important Precautions:** * **Species Restriction:** Do NOT use in cats. Rapid weight loss in obese cats significantly increases the risk of fatal hepatic lipidosis. * **Endocrine Disease:** Pre-existing endocrine diseases (like Cushing's or hypothyroidism) must be managed prior to initiating dirlotapide therapy. * **Duration of Use:** Safe use for longer than one year has not been evaluated. * **Reproductive Safety:** Safety in breeding, pregnant, or lactating dogs has not been established. * **Hepatic Effects:** May cause mild to moderate elevations in serum hepatic transaminases early in treatment.

약물 상호작용

• Narrow therapeutic index oral drugs: Potential altered absorption rate and extent; administer at least 2 hours prior to dirlotapide.
• Fat-soluble vitamins (A, E, K): Decreased plasma concentrations during the initial treatment phase; levels typically stabilize and recover during the weight stabilization phase.

자주 묻는 질문